In patients with gynecological cancers (n = 25,894), the HR for ATE with VEGF-targeted therapy (n = 1788) was 1.18 (95% CI: 0.74–1.87), and the HR for VTE was 1.82 (95% CI: 1.46–2.26). Here, VEGFA is linked to female reproductive organ cancer.